3. As of noon trading, Covidien ( COV) is up $0.40 (0.7%) to $57.81 on average volume. Thus far, 1.7 million shares of Covidien exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $57.41-$58.20 after having opened the day at $57.42 as compared to the previous trading day's close of $57.41.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $29.6 billion and is part of the health care sector. The company has a P/E ratio of 16.3, below the S&P 500 P/E ratio of 17.7. Shares are up 8.8% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Covidien Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Zimmer Biomet's Prognosis Is Promising

Zimmer Biomet's Prognosis Is Promising

St. Jude Buying Thoratec Could Resusitate Medtech M&As

Analysts' Actions -- AT&T, Fitbit, Netflix and More

Barbarian At The Gate: Zimmer Holdings (ZMH)

Deal Delay Minor Obstacle for Zimmer

Deal Delay Minor Obstacle for Zimmer